Safety of switching from brand-name to generic levetiracetam in patients with epilepsy
Authors:
Open Access
- 1 August 2017
- journal article
- research article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 11, 2287-2291
Abstract
Purpose: The approach to the use of generic antiepileptic drugs has recently evolved from major concern to general acceptance, but the evidence related specifically to the safety of switching from brand-name to generic levetiracetam (LEV) is scarce. The aim of the study was to assess the risk of increased frequency of seizures or other adverse events after replacement of a brand-name LEV with a generic one. Patients and methods: This retrospective analysis included 159 patients treated with LEV in a tertiary outpatient epilepsy clinic. We included all patients diagnosed with epilepsy who were treated with LEV as at March 1, 2013. Most patients were forced to switch to the generic LEV because of the sudden rise in cost of the branded LEV. We recorded data on age, sex, age at onset of epilepsy, type of epilepsy, and its treatment. We analyzed data from one visit before potential switching and from two visits after the potential switching. The interval between visits was typically 3 months. We registered an increase in the frequency of seizures and in the occurrence of adverse events. Results: Among 151 subjects who switched to generic LEV after March 1, 2013, increased frequency of seizures was noted in 9 patients (6%) during the first follow-up visit. Patients with increased frequency of seizures did not differ from other patients regarding sex, age, age at the onset of epilepsy, and the median dose of LEV before switching or the median duration of treatment with LEV before switching. Two patients returned to brand-name LEV. Adverse events were noted in six other patients (4%) and included somnolence, irritability, or dizziness. Conclusion: Switching from brand-name to generic LEV is generally safe.Keywords
This publication has 20 references indexed in Scilit:
- Generic lamotrigine versus brand‐name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standardEpilepsia, 2015
- The Impact on Health Outcomes and Healthcare Utilisation of Switching to Generic Medicines Consequent to Reference Pricing: The Case of Lamotrigine in New ZealandApplied Health Economics and Health Policy, 2014
- Generic Substitution of Lamotrigine Among Medicaid Patients with Diverse IndicationsCNS Drugs, 2012
- Clinical experience with generic levetiracetam in people with epilepsyEpilepsia, 2011
- Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug AdministrationAnnals of Pharmacotherapy, 2009
- Effects of Antiepileptic Drug Substitutions on Epileptic Events Requiring Acute CarePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009
- The risks and costs of multiple-generic substitution of topiramateNeurology, 2009
- Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsyNeurology, 2007
- Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug ClassesEpilepsia, 2007
- Recommendations of the Italian League Against Epilepsy Working Group on Generic Products of Antiepileptic DrugsEpilepsia, 2006